Abstract
Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.
| Original language | English (US) |
|---|---|
| Journal | Expert Opinion on Investigational Drugs |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- Chronic nodular prurigo
- chronic pruritus
- neurokinin 1 receptor
- NK receptor
- prurigo nodularis
- psoriasis
- serlopitant
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. / Ständer, Sonja; Spellman, Mary C.; Kwon, Paul; Yosipovitch, Gil.
In: Expert Opinion on Investigational Drugs, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The NK1 receptor antagonist serlopitant for treatment of chronic pruritus
AU - Ständer, Sonja
AU - Spellman, Mary C.
AU - Kwon, Paul
AU - Yosipovitch, Gil
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.
AB - Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin. Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies. Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.
KW - Chronic nodular prurigo
KW - chronic pruritus
KW - neurokinin 1 receptor
KW - NK receptor
KW - prurigo nodularis
KW - psoriasis
KW - serlopitant
UR - http://www.scopus.com/inward/record.url?scp=85068610789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068610789&partnerID=8YFLogxK
U2 - 10.1080/13543784.2019.1638910
DO - 10.1080/13543784.2019.1638910
M3 - Article
C2 - 31272246
AN - SCOPUS:85068610789
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
SN - 1354-3784
ER -